Potey C, Ouk T, Petrault O, Petrault M, Berezowski V, Salleron J, Bordet R, Gautier S
U1171 - Medical Pharmacology Department, Faculty of Medicine, University of Lille 2 - Lille University Hospital, Lille, France.
EA2694 - Biostatistics Department, Faculty of Medicine, University of Lille 2 - Lille University Hospital, Lille, France.
Br J Pharmacol. 2015 Nov;172(21):5188-98. doi: 10.1111/bph.13285. Epub 2015 Oct 6.
From the clinical and experimental data available, statins appear to be interesting drug candidates for preventive neuroprotection in ischaemic stroke. However, their acute protective effect is, as yet, unconfirmed.
Male C57Bl6/JRj mice were subjected to middle cerebral artery occlusion and treated acutely with atorvastatin (10-20 mg·kg(-1) day(-1) ; 24 or 72 h). Functional recovery (neuroscore, forelimb gripping strength and adhesive removal test) was assessed during follow-up and lesion volume measured at the end. Vasoreactivity of the middle cerebral artery (MCA), type IV collagen and FITC-dextran distribution were evaluated to assess macrovascular and microvascular protection. Activated microglia, leucocyte adhesion and infiltration were chosen as markers of inflammation.
Acute treatment with atorvastatin provided parenchymal and cerebral protection only at the higher dose of 20 mg·kg(-1) ·day(-1) . In this treatment group, functional recovery was ameliorated, and lesion volumes were reduced as early as 24 h after experimental stroke. This was associated with vascular protection as endothelial function of the MCA and the density and patency of the microvascular network were preserved. Acute atorvastatin administration also induced an anti-inflammatory effect in association with parenchymal and vascular mechanisms; it reduced microglial activation, and decreased leucocyte adhesion and infiltration.
Acute atorvastatin provides global cerebral protection, but only at the higher dose of 20 mg·kg(-1) ·day(-1) ; this was associated with a reduction in inflammation in both vascular and parenchymal compartments. Our results suggest that atorvastatin could also be beneficial when administered early after stroke.
从现有的临床和实验数据来看,他汀类药物似乎是缺血性卒中预防性神经保护的理想候选药物。然而,其急性保护作用尚未得到证实。
雄性C57Bl6/JRj小鼠接受大脑中动脉闭塞手术,并急性给予阿托伐他汀(10 - 20毫克·千克⁻¹·天⁻¹;24或72小时)。在随访期间评估功能恢复情况(神经评分、前肢抓握力和黏附去除试验),并在最后测量梗死体积。评估大脑中动脉(MCA)的血管反应性、IV型胶原和异硫氰酸荧光素 - 葡聚糖分布,以评估大血管和微血管保护。选择活化的小胶质细胞、白细胞黏附和浸润作为炎症标志物。
阿托伐他汀急性治疗仅在较高剂量20毫克·千克⁻¹·天⁻¹时提供实质和脑保护。在该治疗组中,功能恢复得到改善,早在实验性卒中后24小时梗死体积就减小。这与血管保护相关,因为MCA的内皮功能以及微血管网络的密度和通畅性得以保留。急性给予阿托伐他汀还与实质和血管机制相关联地诱导了抗炎作用;它减少了小胶质细胞活化,并降低了白细胞黏附和浸润。
急性给予阿托伐他汀可提供全面的脑保护,但仅在较高剂量20毫克·千克⁻¹·天⁻¹时;这与血管和实质部分的炎症减少相关。我们的结果表明,卒中后早期给予阿托伐他汀也可能有益。